HOME >> MEDICINE >> NEWS
Promising drug fails to improve COPD symptoms

NF-, and a number of studies have reported increased production of TNF in COPD patients. This increased production has been linked to weight loss, muscle weakness and muscle loss.

In addition, animal studies supported the prospect using the drug in COPD. When TNF- was infused into rats, they developed emphysema, which, along with chronic bronchitis, makes up most COPD cases. When the TNF- receptor was turned off in mice, they were less likely than mice that had not be genetically altered to develop emphysema when exposed to chronic cigarette smoke.

The latest study, however, did confirm a recently reported pilot study that found no improvement among the 14 COPD patients given infliximab.

In attempting to explain the disappointing results, the study authors speculate that, despite infliximab's efficacy in treating other inflammatory diseases, it may not be effective in COPD because other mediators, in addition to TNF-, are necessary to cause COPD. They also concede that six months may simply be too short a time period to see improvement.

However, an increased number of malignancies observed in infliximab-treated subjects, the authors said, raised concern about the safety of this drug in lung patients. Although the malignancies may have been present when the patients enrolled in the study, "the possibility that infliximab contributed to the progession, and thus the diagnosis, of malignancies remains a serious concern."

This safety issue, coupled with the "resoundingly negative results," make in unlikely that a longer trial will be undertaken, according to the accompanying editorial.


'"/>

Contact: Suzy Martin
smartin@thoracic.org
212-315-8631
American Thoracic Society
1-May-2007


Page: 1 2

Related medicine news :

1. Promising therapy for ALS delivers antisense drug directly to nervous system
2. Promising new treatment for ulcerative colitis sufferers
3. Promising advance in breast cancer research
4. Promising obesity therapy receives follow-on funding
5. Promising diagnostic tools for multiple sclerosis developed at Yale
6. Promising therapies for haemophilia & heart disease
7. Promising new TB drug enters clinical trial
8. Promising new West Nile therapy cures disease in mice
9. Government fails sleepy Judge Dodd
10. Pairing medical therapy with coronary intervention fails to reduce heart disease deaths
11. Community and clinic-based HIV-1 control program fails to decrease incidence of HIV-1 in Zimbabwe

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s Day gift for ... your toes. Foot massage, whether administered by a professional masseuse or a loved one, ... American Board of Multiple Specialties in Podiatry (ABMSP) has taken the upcoming Valentine’s ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... Wine Tasting Event at the La Gorce Country Club in Miami Beach on ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to feel uncomfortable ... safer than regular municipal or well water. The recent experience with lead contaminated water ... go a long way toward increasing public acceptance of recycled waste water as drinking ...
(Date:2/5/2016)... ... 2016 , ... Boar’s Head Brand®, one of the nation’s leading providers of ... Take the stress out of your party preparation – follow these easy, yet delicious ... of the game. , “The key to hosting a successful game-day party is creating ...
(Date:2/5/2016)... ... , ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental ... individuals in need. The event is scheduled to take place on February 27, 2016 ... provide dental care to community members in need. Each patient will be given the ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Bernstein Liebhard LLP today announced that a securities class ... for the District of Arizona on ... or entities who purchased common shares of Insys Therapeutics Inc. ... 3, 2015 through January 25, 2016 (the "Class Period").  The ... of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... 4, 2016 Wegener Polyangiitis - Pipeline ... Direct,s, ,Wegener Polyangiitis - Pipeline Review, H2 2015, ... pipeline. This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
(Date:2/4/2016)... Summary Breast cancer, a malignant neoplasm, is the ... in women worldwide, accounting for 16% of all female ... women diagnosed with breast cancer has increased over the ... declined due to earlier diagnosis and better treatment options. ... past four decades, especially with increasing usage of targeted ...
Breaking Medicine Technology:
Cached News: